Suppl. Figure e-2



Figure e-2: CD19⁺ B to T_{reg} Cell Ratios in Alemtuzumab-Treated Patients With or Without Autoimmune AEs or Disease Activity
Median ratio of (A) total, immature, memory, or mature CD19⁺ B cells to CD4⁺ T_{reg} cells and (B) total, immature, memory, or mature CD19⁺ B cells to CD8⁺ T_{reg} cells in CARE-MS patients treated with alemtuzumab 12 mg, stratified by the presence or absence of autoimmune AEs, relapse, 6-month CDW, and MRI disease activity. N-value range over 24 months: 18–71 patients without autoimmune AEs; 20–75 patients with autoimmune AEs; 13–71 patients without relapse; 23–75 patients with relapse; 27–108 patients without CDW; 11–38 patients with CDW; 14–63 patients without MRI activity; 24–83 patients with MRI activity. Vertical lines indicate administration of alemtuzumab. AE = adverse event; CDW = confirmed disability worsening; IQR = interquartile range; T_{reg} = regulatory T.